Back to discover
§ The cross-read
ABBV vs LLY
LLY's Section-2 severe Pricing Regulation risk is the dominant variable in any cross-read.
Fair-value ladder
Fair-value ladder unavailable — one or both tickers have no published mid fair value.
Aligned scorecards
ABBVLLY
| ABBVAbbVie Inc. | LLYEli Lilly and Company | |
|---|---|---|
| Trend | - | - |
| Price | - | $851 |
| Fair value | - | - |
| FV range | - | - |
| Upside | - | - |
| Rating | Aanhouden | Aanhouden |
| Confidence | - | - |
| Moat | - | - |
| Archetype | - | - |
| Sector | Health Care | Health Care |
| Analyzed | - | - |
9-category scorecards
ABBV
AbbVie Inc.
Valuation
1.5/10
0.11x
Management
7.3/10
0.11x
Balance Sheet
3.0/10
0.11x
Profitability
7.0/10
0.11x
Revenue Growth
6.0/10
0.11x
Risk Assessment
5.5/10
0.11x
Competitive Moat
9.0/10
0.11x
Earnings Quality
7.5/10
0.11x
Capital Efficiency
6.0/10
0.11x
Weighted Overall
5.9/10
LLY
Eli Lilly and Company
Valuation
5.0/10
0.11x
Management
8.1/10
0.11x
Balance Sheet
4.5/10
0.11x
Profitability
8.5/10
0.11x
Revenue Growth
9.0/10
0.11x
Risk Assessment
7.0/10
0.11x
Competitive Moat
9.0/10
0.11x
Earnings Quality
7.5/10
0.11x
Capital Efficiency
7.0/10
0.11x
Weighted Overall
7.3/10